XML 53 R37.htm IDEA: XBRL DOCUMENT v3.20.2
Revenue - Total Revenue by Product and by US versus Rest of World (Details) - USD ($)
$ in Millions
 3 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Disaggregation of Revenue [Line Items]    
Total revenue $ 145.2 $ 186.3
U.S.    
Disaggregation of Revenue [Line Items]    
Total revenue 134.0 174.7
RoW    
Disaggregation of Revenue [Line Items]    
Total revenue 11.2 11.7
Molecular diagnostic - Hereditary Cancer Testing    
Disaggregation of Revenue [Line Items]    
Total revenue 80.6 104.5
Molecular diagnostic - Hereditary Cancer Testing | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenue 72.1 100.6
Molecular diagnostic - Hereditary Cancer Testing | RoW    
Disaggregation of Revenue [Line Items]    
Total revenue 8.5 3.9
Molecular diagnostic - Prenatal    
Disaggregation of Revenue [Line Items]    
Total revenue 16.5 23.5
Molecular diagnostic - Prenatal | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenue 16.4 23.5
Molecular diagnostic - Prenatal | RoW    
Disaggregation of Revenue [Line Items]    
Total revenue 0.1 0.0
Molecular diagnostic - GeneSight    
Disaggregation of Revenue [Line Items]    
Total revenue 11.9 22.7
Molecular diagnostic - GeneSight | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenue 11.9 22.7
Molecular diagnostic - GeneSight | RoW    
Disaggregation of Revenue [Line Items]    
Total revenue 0.0 0.0
Molecular diagnostic - Vectra    
Disaggregation of Revenue [Line Items]    
Total revenue 9.1 11.0
Molecular diagnostic - Vectra | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenue 9.1 11.0
Molecular diagnostic - Vectra | RoW    
Disaggregation of Revenue [Line Items]    
Total revenue 0.0 0.0
Molecular diagnostic - myChoice CDx    
Disaggregation of Revenue [Line Items]    
Total revenue 7.8 1.3
Molecular diagnostic - myChoice CDx | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenue 7.6 1.3
Molecular diagnostic - myChoice CDx | RoW    
Disaggregation of Revenue [Line Items]    
Total revenue 0.2 0.0
Molecular diagnostic - Prolaris    
Disaggregation of Revenue [Line Items]    
Total revenue 6.4 6.5
Molecular diagnostic - Prolaris | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenue 6.4 6.5
Molecular diagnostic - Prolaris | RoW    
Disaggregation of Revenue [Line Items]    
Total revenue 0.0 0.0
Molecular diagnostic - EndoPredict    
Disaggregation of Revenue [Line Items]    
Total revenue 2.8 2.3
Molecular diagnostic - EndoPredict | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenue 0.4 0.5
Molecular diagnostic - EndoPredict | RoW    
Disaggregation of Revenue [Line Items]    
Total revenue 2.4 1.8
Molecular diagnostic - Other    
Disaggregation of Revenue [Line Items]    
Total revenue 0.6 0.2
Molecular diagnostic - Other | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenue 0.6 0.1
Molecular diagnostic - Other | RoW    
Disaggregation of Revenue [Line Items]    
Total revenue 0.0 0.1
Molecular diagnostic testing    
Disaggregation of Revenue [Line Items]    
Total revenue 135.7 172.0
Molecular diagnostic testing | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenue 124.5 166.2
Molecular diagnostic testing | RoW    
Disaggregation of Revenue [Line Items]    
Total revenue 11.2 5.8
Pharmaceutical and clinical services    
Disaggregation of Revenue [Line Items]    
Total revenue 9.5 14.3
Pharmaceutical and clinical services | U.S.    
Disaggregation of Revenue [Line Items]    
Total revenue 9.5 8.5
Pharmaceutical and clinical services | RoW    
Disaggregation of Revenue [Line Items]    
Total revenue $ 0.0 $ 5.9